HOLBROOK, N.Y., Nov. 13, 2013 /PRNewswire/ -- Northstar (OTCPink: MDIN) today announced that it has completed the design and manufactured the first prototypes of its lactose intolerance treatment bringing it one step closer to market. Based on the recently licensed patent, the treatment is like nothing else available, and will make Northstar stand out far among any competitors.

The final design of the product comes in the form of a three-day treatment. Consisting of a pill on days one and two, and consumption of a small a small 1oz container of yogurt on day three, which starts a unique process in the digestive system. Laboratory animals consuming the treatment were rid of all lactose intolerance symptoms for as long as 90 days.

Northstar's CEO, Nick Chieco explained, "Every other solution to this problem involves taking pills before any meal containing lactose. Forgetting to do so, or consuming lactose-containing foods without realizing it can be extremely uncomfortable and even painful for those afflicted. This product does more than offer a treatment for a few uncomfortable symptoms, it offers total freedom to people ordinarily shackled to restrictive diets and carrying around pills everywhere they go." He goes on to say, "The company has been overwhelmed with interest from potential partners, investors, the retail community and others, and despite the success of Snorenz and the other product line, It's my feeling that this, yet unnamed product is going to define Northstar's future even before it is released to the public."

This announcement comes at the end of an extremely busy few months. Currently Northstar has been shipping additional product to retail chains and distributors gearing up for release to shelves on the national level, and although that benchmark in the company's history was originally expected to happen almost a year ago, Northstar would like to assure shareholders that the result will be worth the wait. The company originally planned for release as a promotional display product, but because of solid sales and customer demand, will end up going straight to permanent homes in the shelf plans of some major retailers.  Additionally, the company has been in the middle of auditing it's books for the past two years to become fully reporting, a daunting task that the company hopes to have completed by the first of the year, so it can be released along with the 2013 annual disclosure.

Month after month Northstar's sales continue to grow, and the company continues to gain position for what it hopes is a sprint to the big leagues of alternative healthcare products.

About Northstar
Northstar Global Business Services is dedicated to producing the best alternative healthcare products to the world. The company's varied product line includes Snorenz®, Snorenz Night Time ™, Good Night's Sleep®, Stem-Intense, and Health Enrich for Pets™. Most of the company's products use a unique or patented spray delivery system, and all have received rave consumer reviews all over the world, selling millions of units from 1996 to the present. For more information about Northstar, Contact Investor Relations at 1-877-571-4387 or Email: investors@northstarbb.com

DISCLAIMER
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.

SOURCE Northstar Global Business Services

Copyright 2013 PR Newswire

MedGen (CE) (USOTC:MDIN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more MedGen (CE) Charts.
MedGen (CE) (USOTC:MDIN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more MedGen (CE) Charts.